Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK) and has been approved for several B-cell malignancies, including R/R ABC DLBCL, possibly related to the chronic activation of B-cell receptor and NF-κB patterns which characterize this COO subtype [148]. Here, BTK is linked to aneurysmal bone cyst.